Newsletter #7
Focus on Tau oligomers in Alzheimer's disease
Tau oligomers:
a new tool for drug discovery in AD
After a year of hard work, we have succeeded in generating soluble, stable tau oligomers at a concentration sufficient to induce significant toxicity in primary neuron cultures. This new in vitro model of Alzheimer’s Disease stands ready to screen molecules. Find out about the main validation results.
6 reasons to include tau oligomers in your R&D strategy for the treatment of AD
The scientific literature shows that tau oligomers have been receiving increasing attention over the past 20 years. While several forms of tau are being studied, the most recent work suggests a key role for oligomeric forms in AD. Here are 6 reasons to integrate trials featuring tau oligomers to your R&D strategy.
Tau Clinical Trials
What can be learned from failure?
The tau protein is already the subject of numerous clinical trials. Here you’ll find an up-to-date summary of the various therapeutic strategies currently in development (immunotherapy, anti-aggregation strategy, microtubule stabilisation, etc.) as well as the stage of clinical development they have reached.
New hope for AD: what’s combining therapeutic strategies all about?
Alzheimer’s Disease is a multifactorial, progressive pathology with many facets (proteinopathies, inflammation, cerebral metabolic disorders, etc.). Its etiology remains poorly understood. For the time being, finding the miracle molecule seems unattainable. Could a combination of treatments be the winning strategy?
